A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-03

Study Completion Date

2025-05-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is testing a new medicine to potentially treat people with heart failure. The main purpose of the study is to see if the new study medicine is safe and how it works in the body. It is the first time NNC0537-1482 (the new study medicine) is tested in humans and will be tested in healthy individuals (men and postmenopausal women). Participant will either get NNC0537-1482 or placebo (a "dummy medicine" without any active ingredients). Which treatment the participant get is decided by chance and the participant will only get either the study medicine or placebo on one occasion. It will be injected under the skin of the stomach by the study staff and the number of injections will depend on the cohort participant is assigned to. NNC0537-1482 cannot be prescribed by doctors. The study consists of 6 cohorts (groups) with 6 different dosing levels. The study will last for about 9 months. Participation in the study will last up to 42 days (depending on the cohort participant are assigned to) with an additional screening period that can be up to 28 days. Participant will have up to 10 visits to the clinic during the study period. However, the total number of visits depend on which cohort participant is assigned to.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure

NCT07218627

Heart Failure

RECRUITING PHASE1

A Study of CK-1827452 Infusion in Stable Heart Failure

NCT00624442

Heart Failure

COMPLETED PHASE2

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

NCT05659264

Chronic Heart Failure

COMPLETED PHASE1

Sub-Q Versus IV Furosemide in Acute Heart Failure

NCT02579057

Congestive Heart Failure

COMPLETED PHASE2/PHASE3

Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention

NCT07318103

Fluid Retention Caused by Heart Failure

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Sponsor staff involved in the clinical trial is masked according to company standard procedures

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NNC0537-1482

Administered via subcutaneous route

Intervention Type DRUG

Placebo

Administered via subcutaneous route

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or postmenopausal female.
* Age 22-55 years (both inclusive) at the time of signing the informed consent.
* Body Mass Index (BMI) between 18.5 and 30.0 kilogram/meter per square (kg/m\^2) (both inclusive) at screening.
* Considered eligible and generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria

* Known or suspected hypersensitivity to study intervention(s) or related products.
* Use of prescription or non-prescription medicinal products, including herbal medications, within 14 days before screening. Occasional use of over-the-counter vitamins, or paracetamol or Non-steroidal anti-inflammatory drugs (NSAIDs) at their labelled doses for mild pain is permitted.
* Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
* Orthostatic hypotension, defined as a decrease in systolic blood pressure greater than or equal to 20 millimetres of mercury (mmHg) or a decrease in diastolic blood pressure greater than or equal to 10 (mmHg) from supine to standing after 3 minutes, at the screening visit.
* Any laboratory safety parameters at screening outside the below laboratory ranges for:

* Alanine Aminotransferase (ALT) greater than (\>) Upper normal limits (UNL) plus (+) 10 Percentage (%)
* Aspartate Aminotransferase (AST) \> Upper limit normal (ULN) +20%
* Bilirubin \> ULN + 20%
* Creatinine \> ULN + 10%

Minimum Eligible Age

22 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes